Radioiodine treatment: an historical and future perspective

in Endocrine-Related Cancer
View More View Less
  • 1 P Borges de Souza, Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
  • 2 C McCabe, IMSR, University of Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland

Correspondence: Chris McCabe, Email: C.J.MCCABE.MED@bham.ac.uk

Radioiodine (RAI) therapy has been used to treat thyroid diseases for around 80 years, and yet it is only relatively recently that we are beginning to manipulate its use, as we understand more of the cellular complexities which govern its success. From the benign nature of hyperthyroidism to malignant thyroid carcinomas and their metastases, RAI has profoundly changed the management of thyroid disorders. However, the complex journey which has elicited this simple therapy is worth exploring.

 

Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 224 224 52
PDF Downloads 249 249 48